<DOC>
	<DOCNO>NCT01024959</DOCNO>
	<brief_summary>The objective multi-center clinical study determine association PCA3 Score prostate biopsy outcome validate assay 's performance characteristic men previous negative prostate biopsy . An elevated PCA3 Score think associate increase likelihood positive biopsy . The result study intend use regulatory filing use vitro diagnostic test .</brief_summary>
	<brief_title>Clinical Evaluation PROGENSA ( Registered Trademark ) Prostate Cancer Gene 3 ( PCA3 ) Assay Men With Previous Negative Biopsy Result</brief_title>
	<detailed_description>PCA3 gene highly over-expressed 90 % prostate cancer , quantify urine specimen follow digital rectal examination . Studies show PCA3 highly specific prostate cancer , predict result repeat biopsy accurately traditional prostate-specific antigen ( PSA ) test . Gen-Probe 's PROGENSA ( R ) PCA3 assay first urine-based molecular diagnostic assay prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 40+ year age least 1 previous negative prostate biopsy , never positive prostate biopsy , recommend repeat biopsy clinician . The subject must able comprehend sign approve informed consent form applicable study enrollment document Use medication hormone know affect serum PSA level within 3 6 month study enrollment Clinical symptom urinary tract infection ( include prostatitis ) time enrollment History prostate cancer History invasive treatment benign prostatic hypertrophy ( BPH ) low urinary tract symptom within 6 month study enrollment Medical history concurrent illness investigator considers sufficiently serious interfere conduct , completion , result trial , constitute unacceptable risk subject Participation pharmaceutical treatment related clinical study within 6 month study enrollment . Exception : Trials nonprostate condition may acceptable , approval investigator Sponsor</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Biopsy</keyword>
	<keyword>PCA3</keyword>
</DOC>